Can You Buy HRT Over the Counter?

Most forms of hormone replacement therapy require a prescription in the United States, the United Kingdom, and most other countries. The exceptions are narrow: certain low-dose vaginal estradiol tablets became available from pharmacists without a prescription in the UK in 2022, and over-the-counter progesterone creams have been sold in the US for years as cosmetic or supplement products. But the systemic estrogen, progesterone, and testosterone formulations that most people mean when they say “HRT” remain firmly behind a prescription gate, and there are genuine medical reasons for that.

The One True Over-the-Counter Exception in the UK

In 2022, the UK’s Medicines and Healthcare products Regulatory Agency reclassified Gina vaginal tablets, which contain 10 micrograms of estradiol, from prescription-only to a pharmacy medicine. That means you can walk into a pharmacy and buy them after a brief consultation with the pharmacist, without seeing a doctor first.¹ This was a landmark move, and it remains one of the only examples worldwide of a regulated estrogen product being made available without a prescription.

The reason regulators felt comfortable with this reclassification is that ultra-low-dose vaginal estradiol barely enters the bloodstream. Studies show that vaginal administration of 10 micrograms of estradiol results in negligible to very low systemic absorption in postmenopausal women, while still relieving symptoms of vaginal dryness and discomfort as early as two weeks into treatment.² Because so little estrogen reaches the rest of the body, the risks that make systemic HRT prescription-only don’t really apply here. The product is intended for vaginal dryness and related urogenital symptoms, not for hot flashes, bone loss, or other systemic effects of menopause.

Outside the UK, no country has followed suit with an equivalent reclassification for estrogen products, though advocates in Australia and elsewhere have pushed for it. In the US, no estrogen-containing product of any kind is available over the counter.

Why Systemic HRT Stays Behind a Prescription

The medical case for keeping systemic hormone therapy prescription-only centers on a few well-established risks that need professional monitoring. The most important is what happens to the uterine lining when estrogen is used alone. A Cochrane review of randomized trials found that unopposed estrogen roughly multiplied the risk of endometrial hyperplasia by six within a year, and the risk climbed further with longer use.³ That risk is the reason anyone with a uterus using systemic estrogen needs a progestogen alongside it, and choosing the right combination and dose is a clinical decision.

Blood clot risk is another reason for medical oversight. Research from the Women’s Health Initiative found that certain biomarkers, particularly D-dimer levels, could identify women at higher risk of venous thrombosis when taking oral hormone therapy.⁴ Factors like personal or family history of clots, smoking, obesity, and age all influence whether hormone therapy is safe for a given person. A pharmacist handing tablets across the counter cannot evaluate these risks the way a prescriber working with lab results can.

None of this means HRT is inherently dangerous. For many women, the benefits comfortably outweigh the risks. But the point is that someone needs to assess which side of that equation you fall on, and that assessment requires more than a pharmacy counter conversation.

OTC Progesterone Creams and Why They’re Controversial

Walk into a health food store or browse a supplement website in the US and you’ll find progesterone creams sold without a prescription. These products occupy a regulatory gray area: they’re classified as cosmetics rather than drugs by the FDA, which means they avoid the prescription requirement entirely. Thousands of postmenopausal women use them.⁵

The science behind them is genuinely complicated. One pharmacokinetic study found that an over-the-counter progesterone cream produced drug exposure comparable to an FDA-approved oral progesterone capsule when doses were normalized, meaning the hormone does get absorbed through the skin in meaningful amounts.⁶ But here’s the catch: serum (blood) levels of progesterone after applying these creams tend to be very low, even though levels measured in saliva and capillary blood are high. That discrepancy makes it hard to know whether the progesterone is actually reaching the uterine lining in concentrations high enough to protect it from the effects of estrogen.

A separate review characterized the evidence base for these creams as inconsistent, noting concerns about the credibility of some non-peer-reviewed studies and the complex pharmacokinetics involved. It concluded that using progesterone cream for postmenopausal therapy should be considered unsubstantiated and restricted to well-designed clinical trials.⁷ The practical upshot is that if you’re using estrogen therapy and relying on an OTC progesterone cream to protect your uterus, you’re taking a gamble that the current evidence doesn’t fully support. This is one area where the gap between “available without a prescription” and “proven safe to use without medical guidance” is wide.

DHEA Supplements

Dehydroepiandrosterone, or DHEA, is another hormone you can buy over the counter in the US as a dietary supplement. Your adrenal glands naturally produce DHEA, and the body converts it into both estrogen and testosterone in peripheral tissues. DHEA levels drop steeply with age, falling by roughly 60% around menopause.⁸

Vaginal DHEA has been studied for urogenital symptoms of menopause with some encouraging results. Research has shown that intravaginal DHEA over 12 weeks reduces vaginal pH, improves the vaginal maturation index, and helps with sexual dysfunction symptoms like dryness and pain during sex, with improvements of about 40% over placebo for the most bothersome symptoms.⁸ However, the FDA-approved vaginal DHEA product (prasterone, sold as Intrarosa) is prescription-only. The OTC DHEA supplements sold in pill or capsule form are a different story: oral DHEA is not well studied for menopausal symptom relief, and what your body does with a swallowed DHEA pill is less predictable than what happens with a targeted vaginal application. In many countries outside the US, DHEA supplements aren’t available over the counter at all.

Herbal Supplements That Claim to Work Like HRT

Black cohosh, red clover, evening primrose oil, soy isoflavones, and various other plant-derived products are heavily marketed to menopausal women as natural alternatives to HRT. All are available without a prescription. The evidence behind them is, to put it diplomatically, uneven.

Black cohosh has shown some ability to reduce the frequency and intensity of hot flashes, particularly in studies of breast cancer patients taking tamoxifen.⁹ One head-to-head trial comparing black cohosh to evening primrose oil found that black cohosh significantly reduced hot flash frequency and severity after eight weeks, while evening primrose oil did not produce a meaningful change in hot flash frequency.¹⁰

But when black cohosh was compared against both a placebo and actual hormone therapy in a rigorous randomized trial, the results were sobering. After 12 months, the black cohosh group saw a 34% reduction in vasomotor symptoms, while the placebo group saw a 63% reduction and conventional hormone therapy achieved a 94% reduction. Black cohosh did not perform significantly better than placebo.¹¹ Red clover fared no better in that same trial. The results are a useful reminder of how powerful the placebo effect can be for subjective symptoms like hot flashes, and why you should be skeptical of supplement marketing that implies these products work like hormone therapy. They may take the edge off for some people, but they are not pharmacological substitutes for estrogen.

Compounded “Bioidentical” Hormones

Compounding pharmacies that custom-mix hormone preparations have become a booming industry, partly because they’re perceived as more “natural” than mass-produced pharmaceuticals. Many compounding pharmacies use the term “bioidentical hormone” as a marketing term to imply their products are safer and more effective than FDA-approved medications. The American College of Obstetricians and Gynecologists addressed this directly in a 2023 clinical consensus statement, noting that evidence to support marketing claims of superior safety and effectiveness is lacking, and that compounded bioidentical menopausal hormone therapy should not be routinely prescribed when FDA-approved formulations exist.¹²

The irony is that many FDA-approved hormone products already use bioidentical hormones. Estradiol patches, for instance, contain the same molecule your ovaries once produced. The distinction between “compounded bioidentical” and “FDA-approved bioidentical” is largely one of regulation and quality control, not chemistry. Compounded products aren’t subject to the same manufacturing standards, batch-to-batch consistency testing, or labeling requirements as FDA-approved drugs. Some compounding pharmacies require a prescription; others operate in grayer territory. Either way, the “natural” framing can lead people to underestimate the real hormonal effects, including the endometrial risks of estrogen and the need for monitoring.

Non-Hormonal Prescription Alternatives

For people who want relief from hot flashes but can’t or prefer not to take hormones, a new class of prescription drugs has arrived. In May 2023, the FDA approved fezolinetant, which works by blocking a receptor in the brain’s temperature-regulation center rather than replacing hormones. In clinical trials, it significantly reduced both the frequency and severity of vasomotor symptoms compared to placebo, with improvements visible as early as one week and maintained over a year.¹³ A systematic review of the broader drug class confirmed moderately strong evidence that these receptor-blocking medications help limit hot flash frequency and severity in menopausal women.¹⁴

Fezolinetant is prescription-only, but it’s worth knowing about because it fills a gap for people with a history of breast cancer, blood clots, or other conditions that rule out hormone therapy. It won’t help with vaginal dryness, bone loss, or the other non-vasomotor effects of menopause, but for hot flashes specifically, it represents a genuine alternative rather than a supplement with ambiguous evidence.

Testosterone for Men

If you’re a man looking into testosterone replacement therapy, the answer is even more clear-cut: testosterone is a Schedule III controlled substance in the United States, meaning it carries additional legal restrictions beyond a standard prescription.¹⁵ It’s monitored through state Prescription Drug Monitoring Programs alongside opioids and other controlled medications. You cannot legally buy testosterone over the counter anywhere in the US, and the same is true across most of the developed world. The “testosterone booster” supplements sold in gyms and online are not testosterone; they’re typically blends of amino acids, herbs, and minerals with little evidence of meaningfully raising testosterone levels.

Self-Sourcing Hormones Online

The gap between what people want and what they can legally access has created a thriving gray market. Researchers examining online pharmacies in Spain found that HRT drugs were being sold without requiring a medical consultation or prescription, and the sites didn’t include registered company details or differentiate between patient and professional information.¹⁶ This isn’t limited to Spain. Unregulated online pharmacies operating from various countries will ship hormone products to customers in places where those same products require a prescription.

The risks of buying hormones this way go beyond the legal ones. Without medical screening, you don’t know whether estrogen therapy is safe for you. Without monitoring, you won’t catch early signs of endometrial changes or other complications. And without quality assurance, you don’t know whether the pills or patches contain what the label says. The problem of self-sourcing is especially acute in the transgender community, where a systematic review found that individuals seeking gender-affirming hormone therapy sometimes self-manage due to difficulty finding knowledgeable and non-stigmatizing providers, lack of access to services, high costs, and a desire for faster transition.¹⁷ These are understandable motivations, but they underscore a failure of healthcare access rather than a safe alternative.

Telehealth and the New Access Landscape

One development that has blurred the line between “over the counter” and “prescription” is the rise of telehealth menopause services. Direct-to-consumer digital health companies now offer virtual consultations where you can speak with a prescriber, get evaluated, and have hormone therapy shipped to your door, sometimes within days. These services are meeting a real need, particularly for people who don’t have a menopause-literate doctor locally or who face long wait times. They are still prescription-based, but they’ve dramatically lowered the effort required to get a prescription for many people.

Telehealth doesn’t eliminate the need for medical assessment. A good telemedicine service will still take a thorough history, screen for contraindications, and require follow-up visits. But it does mean that the practical barriers to getting HRT, which for many women were the real obstacle, have shrunk considerably. If you’ve been considering hormone therapy and your local options feel limited, telehealth is worth exploring as a legitimate route.

Affordability as the Bigger Barrier

In much of the world, the question isn’t whether HRT requires a prescription but whether anyone can afford it regardless. A study examining pricing across low- and middle-income countries found staggering disparities. In Nigeria, the cost of one hormone therapy product amounted to more than 260 days of minimum-wage work. In Sri Lanka, an intrauterine device used for hormone delivery would cost over 150 days’ wages. Even in Brazil, the same device required more than 21 days of work. By contrast, some formulations in Malaysia cost a fraction of a day’s wages.¹⁸ High out-of-pocket costs restrict access to essential menopausal treatments across the developing world, making the prescription-versus-OTC debate largely irrelevant for hundreds of millions of women.

How the WHI Fallout Still Shapes Access

To understand why HRT access feels the way it does today, you need to know what happened in 2002. The Women’s Health Initiative, a large US government-funded trial of estrogen-plus-progestin therapy, was stopped early after finding that the hormone combination carried more risk than benefit for the specific population studied.¹⁹ The results received enormous media coverage and caused widespread fear among both patients and doctors. Prescribing rates dropped sharply: the rate at which new patients started HRT fell from about 8.6% before the study to 2.8% after, and the proportion of existing users who continued therapy fell from 84% to 62%.²⁰

Over the two decades since, the medical community has substantially revised its interpretation of the WHI data. The study’s participants were on average in their mid-60s and a decade past menopause, making them a poor match for the typical woman starting HRT in her late 40s or 50s. Newer analyses and subsequent studies have shown that for younger, recently menopausal women, the risk-benefit profile of hormone therapy is considerably more favorable. But the cultural aftershock of the WHI hasn’t fully faded. Many primary care providers remain hesitant to prescribe HRT, menopause gets limited attention in medical training, and the regulatory caution around making any estrogen-containing product available without a prescription is, at least in part, a legacy of that 2002 moment. The result is a system where getting HRT is medically appropriate for many more people than currently receive it, while making it freely available over the counter would create real safety problems for a subset of users. The prescription requirement is both a reasonable safeguard and a barrier that the healthcare system hasn’t done enough to lower through other means.